{"id":84985,"date":"2026-09-17T17:27:00","date_gmt":"2026-09-17T17:27:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=84985"},"modified":"2026-09-18T00:58:27","modified_gmt":"2026-09-18T00:58:27","slug":"major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/","title":{"rendered":"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight"},"content":{"rendered":"<p><em>The major depressive disorder clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline major depressive disorder drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/em><\/p>\n<p align=\"justify\">New York, USA, Sept.  17, 2026  (GLOBE NEWSWIRE) &#8212; <b>Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight<\/b><\/p>\n<p align=\"justify\"><b><i>The major depressive disorder clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline major depressive disorder drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/i><\/b><\/p>\n<p align=\"justify\">DelveInsight\u2019s &#8216;Major Depressive Disorder Pipeline Insight 2026&#8217; report provides comprehensive global coverage of pipeline therapies for major depressive disorder across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the major depressive disorder domain.<\/p>\n<p align=\"justify\"><b>Major Depressive Disorder Clinical Trial Analysis Summary<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">DelveInsight\u2019s major depressive disorder pipeline report depicts a robust space with<b> 75+ <\/b>active players working to develop <b>75+ <\/b>pipeline major depressive disorder drugs.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Key major depressive disorder companies, such as<b> Helus Pharma, Johnson &amp; Johnson, Alto Neuroscience, Transneural Therapeutics, Synphatec, ACADIA Pharmaceuticals, GH Research, SIMR Biotech, Supernus Pharmaceuticals, Inc., Neurocrine Biosciences, Takeda, Xenon Pharmaceuticals Inc., Eli Lilly and Company, AbbVie Inc., Autobahn Therapeutics, <\/b>and others, are evaluating new major depressive disorder drugs to improve the\u00a0treatment landscape.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Promising pipeline major depressive disorder therapies, such as <b>HLP003, Seltorexant, ALTO-300, TN-001, SP-101, ACP-211, Mebufotenin, SPN-820, Osavampator, Azetukalner, ALTO-202, Brenipatide, Icalcaprant, Elunetirom, <\/b>and others, are in different phases of major depressive disorder clinical trials.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Approximately 12+ major depressive disorder drugs are in the late stages of development.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Notable MoAs in major depressive disorder clinical trials include <b>5-HT2A receptor agonist, Orexin receptor type 2 antagonists, Melatonergic agonist and serotonergic antagonist, NMDA receptor antagonists, Serotonin (5-HT) agonist, Negative allosteric modulator of the GluN2B subunit of the NMDA receptor, Dual 5-HT2A partial agonist\/5HT2B antagonist, ,GLP-1\/GIP agonist, kappa opioid receptor (KOR) antagonist, CNS-TR agonist\u00a0 <\/b>and others.<\/li>\n<\/ul>\n<p align=\"justify\">Request a sample and discover the recent advances in major depressive disorder treatment @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sEPL7uIlNKL_x13DRyZ_phiTJm_9ql5woH2LSYULT6GDzGOXM41rjxCLMcxMnN54ZSCZ6FqKph91nqyYdhpLMqZymSUvE5xZ2sJ6g-Kc8KcbUJT8KX8ljTWNVQy2WzZYKna0O0Ow8TlZ25FgR8516o4Pc5Ccw8xRV8XzYX9AfLMUgDcp00plL_IOOLQAm6f1uMi3K_gSLejF6RXisg7tA__vbb6pYGmz6ZC3AW7u21m_gUQcJblyk-1JsvWVZJc32XoMnhNTEXiEDomxsIsBd34pr-quRlsl1JQT365_PENycAjsy9_A58fNawqaQ8OmZYx8_JxyzyN5emwHLhsXX8m_Ld788ysJ2FPLcAvpElg=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight<\/b><\/a><\/p>\n<p align=\"justify\"><b>What is Major Depressive Disorder?<\/b><\/p>\n<p align=\"justify\">Major Depressive Disorder (MDD), commonly known as depression, is a serious and prevalent mental health disorder characterized by persistent feelings of sadness, hopelessness, or loss of interest or pleasure in previously enjoyable activities. It can affect mood, thoughts, behavior, sleep, appetite, energy levels, concentration, and overall daily functioning. MDD can develop due to a combination of genetic, biological, psychological, and environmental factors and may vary in severity from mild to severe. Unlike temporary feelings of sadness, depressive symptoms typically persist for at least two weeks and can significantly interfere with an individual\u2019s personal, social, and professional life. Treatment generally involves psychotherapy, antidepressant medications, or a combination of both, with treatment approaches tailored to the severity and needs of each patient.<\/p>\n<p align=\"justify\"><img decoding=\"async\" alt=\"\" data-mce-style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/ca656719-abe2-46a2-b4b7-7d629fcce7b5\/major-depressive-disorder-pipeline.jpg\" style=\"display:block; margin-left:auto; margin-right:auto;\" data-dpi=\"96\" data-filename=\"Major-Depressive-Disorder-Pipeline.jpg\" \/><\/p>\n<p align=\"justify\">Find out more about treatment for major depressive disorder @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pBy61ov_PwRsOuYQIvJCHKFXMduFCvag2p2xJTSw30Qe_PHQ57QVMX0SRYHIKyb4j_4aKncKzCmIydz9xaQl2eSsTrBo7q1VCZMmBDYxQG_d7zEdDpyG9z4m2kGfRC2kveVB70ILcqEtua7unIsUzpl_R190ClXcB7GDVwn5YSIgyGeOznuf9N40ZIW4Lo4JfMN-lYbxfPXspWiujkPnQOOtkvj1NW9FLjWElPWNJ7FTtX3xiNZHj7BA0YP77FQq0UwamBM7ebONGEO_HuzvtBkAaJNsn_0a8DkxRktDt1A=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Major Depressive Disorder New Treatment<\/b><\/a><\/p>\n<p align=\"justify\"><b>A snapshot of the Pipeline Major Depressive Disorder Drugs mentioned in the report:<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Drugs<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Phase\u00a0<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>MoA<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>RoA<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">HLP003<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Helus Pharma<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">III<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">5-HT2A receptor agonist<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Seltorexant<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Johnson &amp; Johnson<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">III<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Orexin receptor type 2 antagonists<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">ALTO-300<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alto Neuroscience<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Melatonergic agonist and serotonergic antagonist<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">ACP-211<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">ACADIA Pharmaceuticals<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">NMDA receptor antagonists<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Mebufotenin<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">GH Research<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Serotonin (5-HT) agonist<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Inhalation<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">ELE-101<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">AtaiBeckley<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Intravenous<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">SP-101<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Synphatec<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">I<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">NMDA receptor antagonists<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Intravenous<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TN 001<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Transneural Therapeutics<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Preclinical<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dual 5-HT2A partial agonist\/<\/p>\n<p>5HT2B antagonist\u00a0<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Unspecified<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Learn more about the major depressive disorder research @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pBy61ov_PwRsOuYQIvJCHKFXMduFCvag2p2xJTSw30RyHwVmlG0oLS5FlKedAZkn-34_AUYW8EoJEHX63jXVgU7Jo_t2s8b0CTrwtJlv_A8CZmIGdsx-4gBoUym-_Wtml-xFIwSB6VghT2fpyh8kbRPAedvfmah0obVoqTYcQ_D_NR5eA1TI8V7pcsZAKFnGg0Atw1SRaH16mlTsaBbWWsPVtz51ptoqr47nxfnZOmO83ezH-0Sz-VhzrQ0s8Zd1RdGEUUrmBPGhHR2ZLbFLAfRYUnhuBZXZpTxKrmveN_8=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Major Depressive Disorder Clinical Trials<\/b><\/a><b>\u00a0<\/b><\/p>\n<p align=\"justify\"><i>As per Stuti Mahajan, consulting manager at DelveInsight, the MDD treatment landscape is shifting toward rapid-acting and mechanistically differentiated therapies, with growing interest in psychedelics, neuroplasticity, glutamatergic signaling, orexin modulation, and precision psychiatry. HLP003 and seltorexant are among the most advanced candidates in Phase III, while ALTO-300, ALTO-202, and TN-001 expand the pipeline through circadian, NMDA, and non-hallucinogenic neuroplasticity mechanisms. Positive developments for DT120, VLS-01, BPL-003, and osavampator further support strong pipeline momentum. The future market outlook remains positive, driven by unmet needs in treatment-resistant depression, demand for faster and durable responses, and increasing treatment personalization, with the global MDD market projected to grow at a healthy rate over the coming years. However, regulatory requirements, safety, tolerability, reimbursement, and competition from established antidepressants will remain key factors influencing market adoption.<\/i><\/p>\n<p align=\"justify\"><b>Recent Developments in Major Depressive Disorder Treatment Space<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2026, Helus Pharma<\/b> announced that it has completed enrollment in its APPROACH Phase III pivotal study of HLP003 in patients living with Major Depressive Disorder.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2026, AtaiBeckley Inc.<\/b> announced that the last patient has been dosed in the Phase IIb Elumina trial evaluating VLS-01 for treatment-resistant depression (TRD). Topline data are expected by fourth quarter of 2026, and, subject to positive Phase II results and regulatory alignment, the company plans to advance VLS-01 into a Phase III program for major depressive disorder.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>June 2026, Definium Therapeutics, Inc.<\/b> announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase III study evaluating a single dose of DT120 (lysergide) ODT 100 \u00b5g in adults with major depressive disorder (MDD).<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>May 2026, Transneural Therapeutics<\/b> announced the presentation of new preclinical data for its lead candidate TN-001 at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting. The preclinical data showed that TN-001 rapidly promoted neuroplasticity and synaptogenesis, while demonstrating significant antidepressant-like effects in a depression model, supporting its potential as a rapid-acting, non-hallucinogenic therapy for major depressive disorder.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>November 2025, Atai Beckley N.V.<\/b> announced the successful completion of the strategic combination between atai Life Sciences and Beckley Psytech Limited in an all-share transaction. The combined company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>September 2025, Neurocrine Biosciences, Inc.<\/b> announced the presentation of new data from the Phase II SAVITRI&#x2122; study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845). In recognition of the data presentation, Neurocrine was honored with the 2025 Poster Award at the 38th annual Psych Congress in San Diego.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>September 2025, Johnson &amp; Johnson<\/b> announced results from the Phase III MDD3005 26-week clinical trial evaluating the efficacy and safety of seltorexant compared to quetiapine extended release (XR) as an adjunctive treatment in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms. The findings were presented at this year\u2019s annual U.S. Psychiatric and Mental Health Congress (Psych Congress), held from September 17-21 in San Diego, California.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2025, Atai Life Sciences and Beckley Psytech Limited <\/b>jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase IIb clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>May 2025, Alto Neuroscience, Inc.<\/b> announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting reinforcing safety and tolerability profile for ALTO-300 in major depressive disorder, in Scottsdale, Arizona, held May 27-30, 2025.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>January 2025, Neurocrine Biosciences, Inc.<\/b> announced the initiation of a Phase III registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (MDD). Positive topline data for the Phase II SAVITRI&#x2122; study of osavampator in adult subjects with MDD were announced in April 2024.<\/li>\n<\/ul>\n<p align=\"justify\"><b>Scope of the Major Depressive Disorder Pipeline Report\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Coverage<\/b>:\u00a0Global\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Major Depressive Disorder Therapeutic Assessment By Product Type: <\/b>Mono, Combination, Mono\/Combination<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Major Depressive Disorder Therapeutic Assessment By Clinical Stages: <\/b>Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Major Depressive Disorder Therapeutics Assessment<\/b> <b>By Route of Administration:<\/b> Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Major Depressive Disorder Therapeutics Assessment<\/b> <b>By Molecule Type<\/b>: Oligonucleotide, Peptide, Small molecule<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Major Depressive Disorder Therapeutics Assessment<\/b> <b>By Mechanism of Action<\/b>: 5-HT2A receptor agonist, Orexin receptor type 2 antagonists, Melatonergic agonist and serotonergic antagonist, NMDA receptor antagonists, Serotonin (5-HT) agonist, Negative allosteric modulator of the GluN2B subunit of the NMDA receptor, Dual 5-HT2A partial agonist\/5HT2B antagonist, ,GLP-1\/GIP agonist, kappa opioid receptor (KOR) antagonist, CNS-TR agonist\u00a0 and others<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Key Major Depressive Disorder Companies<\/b>: Helus Pharma, Janssen Research &amp; Development, Alto Neuroscience, Transneural Therapeutics, Synphatec, ACADIA Pharmaceuticals, GH Research, SIMR Biotech, Supernus Pharmaceuticals, Inc., Neurocrine Biosciences, Takeda, Xenon Pharmaceuticals Inc., Eli Lilly and Company, AbbVie Inc., Autobahn Therapeutics, and others.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Key Major Depressive Disorder Pipeline Therapies<\/b>: HLP003, Seltorexant, ALTO-300, TN-001, SP-101, ACP-211, Mebufotenin, SPN-820, Osavampator, Azetukalner, ALTO-202, Brenipatide, Icalcaprant, Elunetirom, and others<\/li>\n<\/ul>\n<p align=\"justify\">Dive deep into rich insights for major depressive disorder cure, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pBy61ov_PwRsOuYQIvJCHKFXMduFCvag2p2xJTSw30SSIQNHt7DLENKoF9WlKW6pp7FlFNeMKx4yItwofaYsco6DhEvojtna-3L1-lF3Dha9xpaX7E5lT1Kjj9UXzHMtyGzVThio6CPVQoXlpVjt73lA3I_LYl-j1LMWT8DkVpWTX2ej_tD-XsLScHXcBU2sI4T_Gy8ENgwLDCUZiqQsNBoWIQ6RYlYSZPL9iVL5UJp8sPeHa-TKtbPdZKtjW-H0GhcWAU0TrR2611Zkz8bx-pHR3vCoMCOUhIKczN8ZmA8=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Major Depressive Disorder News<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1.<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline Report Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">3.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline: Overview<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">4.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Analytical Perspective In-depth Commercial Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">5.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Clinical Trial Therapeutics<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">6.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline: Late-Stage Products (Pre-registration)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline: Late-Stage Products (Phase III)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">8.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline: Mid-Stage Products (Phase II)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">9.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline: Early-Stage Products (Phase I)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">10.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Major Depressive Disorder Pipeline Therapeutics Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">11.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Inactive Products in the Major Depressive Disorder Pipeline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">12.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Company-University Collaborations (Licensing\/Partnering) Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">13.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Companies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">14.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Products in the Major Depressive Disorder Pipeline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">15.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Unmet Needs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">16.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Market Drivers and Barriers<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">17.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Future Perspectives and Conclusion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">18.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">19.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Appendix<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">For further information on the major depressive disorder clinical trials, reach out @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pBy61ov_PwRsOuYQIvJCHKFXMduFCvag2p2xJTSw30SSVTAkgb78IT_pdGSLTapMKV4Lwp5miF2gdsxBa5QQenawzQB8Qg1ZQUgy7SNTWRF41WJON2woaOFeGBDzlAi7SH9lby3ppp8t3dhqQhAwCxj74mqGebgWlp02-PQjqZmNRa_wjcO00hEf_FINM-fVrp8YYJmYc21z9x70bfNOAovcR2SzTfxjutcS3VdWOEfzZoYA2Mb3xzT2wJ_RJVWBD-KBKNSIxTXFUIii50yqFNS9Rufi8Cejjktuz8Ynebo=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Major Depressive Disorder Medication<\/b><\/a><\/p>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pBy61ov_PwRsOuYQIvJCHKFXMduFCvag2p2xJTSw30RRKJz2eLcO5zgcJWrqt8iTi1BVDh5VXfHHNyDhGFZj6bbo4a_ewwAwcADRcJsN7bEfFzGDCIm8NJSH_Fe5jw9887Dvw8dN43jx8aMuONYQeycmm2LiqpN9oAdPovyBzGMR3nUqfyPy2-a137vQxuEQgWpEhUi3z8IsiO_6qpvjSzEYYkzLJqjRW97CtvHWSJGIoOXIT29dgujOyWk79VLyig5ewY4Y-501sE959FR-Ig==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Major Depressive Disorder Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MDD companies, including <b>Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research &amp; Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Neurocrine Biosciences, Arrivo Bioventures, Sirstei Pharmaceuticals, Alto Neuroscience, Chase Therapeutics, Neumora Therapeutics, Inc., BlackThorn Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Fabre-Kramer Pharmaceuticals, Novartis,<\/b> and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrwQhT_e1QqNMKW8wgMxLNyvKHQIj8n7o7xOVBAeYodww7kh5oRC6xXPrwmlm7GiocQFsnE0eU4PoJJJzVxZpN1cadk60JnIZxNSUdggulrmv7Kb7mAQjiidx9H5mBPVvqvvxy4F7nqA5treXLE64aSyx37hsGuIiX1hdD2IynQtrny6v5hru8UxzoifryAZeS5iwCKeQ4tPqvasy0Nu1llVUHdI1ogPCQMDu47IA8KkSZXxRwSm6pzVxeaDbJgaUlTCuY5wgNC2MVZlUw3Db9I2DIu_Dx8y8Rksi4qprCw=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Generalized Anxiety Disorder Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key generalized anxiety disorder companies including <b>VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics INC., Bionomics Limited, Receptor Life Sciences, MannKind Corporation<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dYaNUxDIdBuHfr8fJgu6XuAv-0hDbiWPq_fYrYT1tWLuoo5llEIrDzkx5o7JljvoWauNuiq1KoL3wB4EnjMzHERtpJqkdklBU3wcSiRAPVTr27kMun4gW8LuFchzoFK_Ui7QDzKeg2iyy0LFAKC-Vo7dUbNMXM6sJnk95vgPgYKi8pdRh7Bn1VQZa9YCkm5FIpJIoXoD0HovQ3HJ6_y5iK67xM7kw-F7VvBqNT2Tk3LaKTKJFn98LGd-MqEk6zRmmaxUGf9JQbGG7cI8fyJhxg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Social Anxiety Disorder Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key social anxiety disorder companies including <b>Mochida Pharmaceutical, Lundbeck, Vistagen Therapeutics, Bionomics, EmpowerPharm<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QHDmUDHZnEv30aSBTkAH63SoklhHhTEHIR8Mjqk3yck_ZbuedEQrHyzDEQ7uH28OA7qPEUW4l03kqBjkVFk4QqCDMYFrrxV2EQEOFkE8_T7uEEl9ySEjcP6WV2nsKuRu6Ls_FOoZ_bbFWFQjU5l9b4piNHKB_s4mJUeOXtg9TjyETsnNxf5KX5qGnpi3oCYSZz9vwnSFoqJdrBW8ae6C7ReXIU5tf8riQnXv5O5dWoyeNAP0Sz57RV0-SeTOsZLE\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer&#8217;s Disease Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Alzheimer&#8217;s Disease Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer&#8217;s disease companies, including <b>Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax &amp; KAEL, AC Immune SA, Johnson &amp; Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QHDmUDHZnEv30aSBTkAH65EE5cRzQdRkcTYeZZbsguQw3bw98roMl27_zIIf5Pk8BIiI1gC3H93toW6BjAZKohPvD3UhIk6DaK0ZFpUPFptAmlqbRXmxUDnnTjRBY2T1FJoKjiyKET7gwxyppSFAZDt-GLTPPT2khM1MexL48Z4ZTMKUX0K5lEGFB-pRQBKNw339Ax1RSneB3vgN9JB7rhgA97iIHBp_AxcpZ94kK8Wa9Mja7oVRGv110Aujqw-si2sZFF8wS45f7034ASSc3YnchHaxo_aJNu4-9qNd5Bo=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer&#8217;s Disease Clinical Trial Analysis\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>Alzheimer&#8217;s Disease Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer&#8217;s Disease companies, including <b>Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,\u00a0 Otsuka Pharmaceutical Co., Ltd.,\u00a0 Cognition Therapeutics, Merck Sharp &amp; Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,\u00a0 Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research &amp; Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., <\/b>and others.<\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<pre>CONTACT: Contact Us\n\nShruti Thakur\u00a0\n\ninfo@delveinsight.com\u00a0\n\n+14699457679<\/pre>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MjQyN2Y4NGEtZjA3Yi00ODk3LWEyMjQtZThhNzg1YjcxMGFkLTEyMDQ5MzgtMjAyNi0wOS0xNy1lbg==\/tiny\/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The major depressive disorder clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline major depressive disorder drugs, clinical strategies, upcoming therapeutics, and commercial analysis. New York, USA, Sept. 17, 2026 (GLOBE NEWSWIRE) &#8212; Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | [&#8230;]\n","protected":false},"author":1,"featured_media":84986,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-84985","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The major depressive disorder clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline major depressive disord\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-17T17:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-18T00:58:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight\",\"datePublished\":\"2026-09-17T17:27:00+00:00\",\"dateModified\":\"2026-09-18T00:58:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/\"},\"wordCount\":2121,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/\",\"name\":\"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-09-17T17:27:00+00:00\",\"dateModified\":\"2026-09-18T00:58:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/","og_locale":"en_US","og_type":"article","og_title":"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight","og_description":"The major depressive disorder clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline major depressive disord","og_url":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-09-17T17:27:00+00:00","article_modified_time":"2026-09-18T00:58:27+00:00","og_image":[{"width":800,"height":420,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight","datePublished":"2026-09-17T17:27:00+00:00","dateModified":"2026-09-18T00:58:27+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/"},"wordCount":2121,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/","url":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/","name":"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-09-17T17:27:00+00:00","dateModified":"2026-09-18T00:58:27+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/major-depressive-disorder-clinical-trial-pipeline-boom-as-75-companies-are-in-the-race-for-better-treatments-delveinsight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=84985"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84985\/revisions"}],"predecessor-version":[{"id":84987,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/84985\/revisions\/84987"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/84986"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=84985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=84985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=84985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}